Stem definition | Drug id | CAS RN |
---|---|---|
systemic antifungal agents, miconazole derivatives | 1800 | 22916-47-8 |
Dose | Unit | Route |
---|---|---|
0.20 | g | O |
1 | g | O |
0.10 | g | V |
1 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.89 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 144.18 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 25 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 7.14 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 9.48 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.08 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 19.75 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 8, 1974 | FDA | INSIGHT PHARMS | |
Dec. 30, 1985 | PMDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
International normalised ratio increased | 228.03 | 16.56 | 103 | 5010 | 43049 | 50556962 |
Drug interaction | 189.29 | 16.56 | 158 | 4955 | 199463 | 50400548 |
Cholestasis of pregnancy | 58.29 | 16.56 | 15 | 5098 | 1116 | 50598895 |
Haemorrhage subcutaneous | 45.40 | 16.56 | 15 | 5098 | 2686 | 50597325 |
Vulvovaginal burning sensation | 44.09 | 16.56 | 13 | 5100 | 1602 | 50598409 |
Haematuria | 41.33 | 16.56 | 28 | 5085 | 25585 | 50574426 |
Sepsis neonatal | 39.05 | 16.56 | 9 | 5104 | 421 | 50599590 |
Pericardial effusion | 38.98 | 16.56 | 27 | 5086 | 25562 | 50574449 |
Encephalitis fungal | 38.98 | 16.56 | 6 | 5107 | 27 | 50599984 |
Nail dystrophy | 28.74 | 16.56 | 8 | 5105 | 803 | 50599208 |
Lip swelling | 28.39 | 16.56 | 22 | 5091 | 24714 | 50575297 |
Cancer pain | 26.71 | 16.56 | 10 | 5103 | 2577 | 50597434 |
Haematoma | 26.35 | 16.56 | 23 | 5090 | 30487 | 50569524 |
Vaginal erosion | 24.49 | 16.56 | 4 | 5109 | 28 | 50599983 |
Axillary pain | 23.46 | 16.56 | 8 | 5105 | 1576 | 50598435 |
Vulvovaginal pruritus | 23.43 | 16.56 | 9 | 5104 | 2487 | 50597524 |
Vulvovaginal candidiasis | 22.77 | 16.56 | 9 | 5104 | 2683 | 50597328 |
Drug ineffective | 22.61 | 16.56 | 30 | 5083 | 819303 | 49780708 |
Drug withdrawal syndrome neonatal | 22.28 | 16.56 | 8 | 5105 | 1833 | 50598178 |
Premature labour | 22.05 | 16.56 | 14 | 5099 | 11462 | 50588549 |
Drug hypersensitivity | 20.75 | 16.56 | 64 | 5049 | 250946 | 50349065 |
Jarisch-Herxheimer reaction | 20.65 | 16.56 | 5 | 5108 | 290 | 50599721 |
Hypokalaemia | 20.56 | 16.56 | 34 | 5079 | 87958 | 50512053 |
Hydronephrosis | 20.46 | 16.56 | 12 | 5101 | 8529 | 50591482 |
Eosinophilia | 20.13 | 16.56 | 16 | 5097 | 18636 | 50581375 |
Rash erythematous | 20.05 | 16.56 | 21 | 5092 | 34831 | 50565180 |
Neuropathy peripheral | 19.48 | 16.56 | 35 | 5078 | 96722 | 50503289 |
Vulvovaginal swelling | 18.66 | 16.56 | 5 | 5108 | 435 | 50599576 |
Pneumomediastinum | 17.77 | 16.56 | 6 | 5107 | 1147 | 50598864 |
Fungal sepsis | 17.77 | 16.56 | 6 | 5107 | 1148 | 50598863 |
Vulvovaginal pain | 17.36 | 16.56 | 7 | 5106 | 2198 | 50597813 |
Vulvovaginal inflammation | 17.11 | 16.56 | 5 | 5108 | 597 | 50599414 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
International normalised ratio increased | 162.49 | 19.02 | 82 | 2881 | 44290 | 29527274 |
Drug interaction | 146.37 | 19.02 | 135 | 2828 | 197250 | 29374314 |
Haematuria | 30.06 | 19.02 | 29 | 2934 | 44110 | 29527454 |
Coagulation time prolonged | 29.90 | 19.02 | 9 | 2954 | 1201 | 29570363 |
Oedema genital | 29.73 | 19.02 | 7 | 2956 | 363 | 29571201 |
Ocular myasthenia | 27.51 | 19.02 | 6 | 2957 | 220 | 29571344 |
Pharyngeal haematoma | 21.94 | 19.02 | 4 | 2959 | 57 | 29571507 |
Haemorrhage subcutaneous | 21.23 | 19.02 | 8 | 2955 | 2117 | 29569447 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
International normalised ratio increased | 298.56 | 16.46 | 152 | 6668 | 79015 | 64412897 |
Drug interaction | 247.47 | 16.46 | 243 | 6577 | 361840 | 64130072 |
Cholestasis of pregnancy | 50.68 | 16.46 | 13 | 6807 | 912 | 64491000 |
Haematuria | 49.31 | 16.46 | 45 | 6775 | 60426 | 64431486 |
Sepsis neonatal | 36.21 | 16.46 | 6 | 6814 | 44 | 64491868 |
Pericardial effusion | 29.64 | 16.46 | 28 | 6792 | 39226 | 64452686 |
Nail dystrophy | 28.36 | 16.46 | 8 | 6812 | 805 | 64491107 |
Oedema genital | 27.78 | 16.46 | 7 | 6813 | 457 | 64491455 |
Drug withdrawal syndrome neonatal | 26.53 | 16.46 | 6 | 6814 | 246 | 64491666 |
Lip swelling | 26.49 | 16.46 | 24 | 6796 | 31883 | 64460029 |
Cancer pain | 24.62 | 16.46 | 11 | 6809 | 4246 | 64487666 |
Vulvovaginal candidiasis | 24.42 | 16.46 | 9 | 6811 | 2121 | 64489791 |
Coagulation time prolonged | 24.36 | 16.46 | 9 | 6811 | 2137 | 64489775 |
Ocular myasthenia | 24.14 | 16.46 | 6 | 6814 | 370 | 64491542 |
Haematoma | 24.06 | 16.46 | 27 | 6793 | 46223 | 64445689 |
Premature labour | 23.97 | 16.46 | 13 | 6807 | 7607 | 64484305 |
Hypokalaemia | 22.98 | 16.46 | 44 | 6776 | 121859 | 64370053 |
Axillary pain | 22.40 | 16.46 | 8 | 6812 | 1724 | 64490188 |
Haemorrhage subcutaneous | 21.23 | 16.46 | 10 | 6810 | 4351 | 64487561 |
Labelled drug-drug interaction medication error | 21.13 | 16.46 | 18 | 6802 | 22044 | 64469868 |
Premature baby | 20.68 | 16.46 | 9 | 6811 | 3263 | 64488649 |
Seizure | 19.80 | 16.46 | 50 | 6770 | 166842 | 64325070 |
Pharyngeal haematoma | 19.34 | 16.46 | 4 | 6816 | 107 | 64491805 |
Contusion | 18.91 | 16.46 | 39 | 6781 | 113926 | 64377986 |
Pneumomediastinum | 18.40 | 16.46 | 8 | 6812 | 2892 | 64489020 |
Urinary tract infection | 18.35 | 16.46 | 60 | 6760 | 231536 | 64260376 |
Eosinophilia | 17.73 | 16.46 | 21 | 6799 | 38055 | 64453857 |
Rash erythematous | 16.62 | 16.46 | 23 | 6797 | 48610 | 64443302 |
None
Source | Code | Description |
---|---|---|
ATC | A01AB09 | ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Antiinfectives and antiseptics for local oral treatment |
ATC | A07AC01 | ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS INTESTINAL ANTIINFECTIVES Imidazole derivatives |
ATC | D01AC02 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives |
ATC | D01AC52 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives |
ATC | G01AF04 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives |
ATC | J02AB01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Imidazole derivatives |
ATC | S02AA13 | SENSORY ORGANS OTOLOGICALS ANTIINFECTIVES Antiinfectives |
FDA CS | M0002083 | Azoles |
FDA EPC | N0000175487 | Azole Antifungal |
MeSH PA | D058888 | 14-alpha Demethylase Inhibitors |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000935 | Antifungal Agents |
MeSH PA | D065688 | Cytochrome P-450 CYP2C9 Inhibitors |
MeSH PA | D065692 | Cytochrome P-450 CYP3A Inhibitors |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D006727 | Hormone Antagonists |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D065088 | Steroid Synthesis Inhibitors |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:75282 | ergosterol biosynthesis inhibitors |
CHEBI has role | CHEBI:82891 | glucocorticoid receptor antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Tinea pedis | indication | 6020002 | DOID:12403 |
Candidiasis of skin | indication | 49883006 | |
Pityriasis versicolor | indication | 56454009 | DOID:9060 |
Candidal vulvovaginitis | indication | 72605008 | DOID:2272 |
Candidiasis of mouth | indication | 79740000 | DOID:14262 |
Tinea corporis | indication | 84849002 | |
Diaper rash | indication | 91487003 | |
Tinea cruris | indication | 399029005 | |
Onychomycosis due to dermatophyte | indication | 402134005 | |
Deep mycosis | indication | 716203000 | |
Oropharyngeal Candidiasis | indication | ||
Paronychia | off-label use | 71906005 | DOID:13117 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Species | Use | Relation |
---|---|---|
Cats | Infections caused by Microsporum canis | Indication |
Cats | Infections caused by Microsporum gypseum | Indication |
Cats | Infections caused by Trichophyton mentagrophytes | Indication |
Dogs | Infections caused by Microsporum canis | Indication |
Dogs | Infections caused by Microsporum gypseum | Indication |
Dogs | Infections caused by Trichophyton mentagrophytes | Indication |
Product | Applicant | Ingredients |
---|---|---|
Conofite Cream 2% | Intervet Inc. | 1 |
Conofite Lotion 1% | Intervet Inc. | 1 |
Surolan | Elanco US Inc. | 3 |
Easotic | Virbac AH Inc. | 3 |
Miconosol | Med-Pharmex Inc. | 1 |
Priconazole Lotion 1% and Spray 1% | First Priority Inc. | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 6.49 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
50MG | ORAVIG | GALT PHARMS | N022404 | April 16, 2010 | RX | TABLET | BUCCAL | 6916485 | Sept. 11, 2022 | TREATMENT OF OROPHARYNGEAL CANDIDIASIS |
50MG | ORAVIG | GALT PHARMS | N022404 | April 16, 2010 | RX | TABLET | BUCCAL | 7651698 | Sept. 11, 2022 | TREATMENT OF OROPHARYNGEAL CANDIDIASIS |
0.25%;81.35%;15% | VUSION | MYLAN | N021026 | Feb. 16, 2006 | RX | OINTMENT | TOPICAL | 8147852 | March 30, 2028 | USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1 adrenergic receptor | GPCR | Ki | 5.14 | DRUG MATRIX | |||||
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 4.59 | DRUG MATRIX | |||||
Cannabinoid receptor 1 | GPCR | Ki | 4.78 | DRUG MATRIX | |||||
Mu-type opioid receptor | GPCR | Ki | 5.61 | DRUG MATRIX | |||||
D(1A) dopamine receptor | GPCR | Ki | 5.51 | DRUG MATRIX | |||||
D(2) dopamine receptor | GPCR | Ki | 5.38 | DRUG MATRIX | |||||
Adenosine receptor A2a | GPCR | Ki | 5.10 | DRUG MATRIX | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.83 | DRUG MATRIX | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | WOMBAT-PK | |||||||
Cytochrome P450 3A4 | Enzyme | IC50 | 7 | DRUG MATRIX | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 6.38 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.54 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.18 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.95 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.45 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.56 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.30 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 5.79 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 5.96 | DRUG MATRIX | |||||
Histamine H2 receptor | GPCR | Ki | 5.18 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.02 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.81 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 6.18 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.35 | DRUG MATRIX | |||||
Beta-3 adrenergic receptor | GPCR | Ki | 5.39 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.87 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 6 | DRUG MATRIX | |||||
Adenosine receptor A1 | GPCR | Ki | 5.14 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 5.80 | DRUG MATRIX | |||||
D(4) dopamine receptor | GPCR | Ki | 5.27 | DRUG MATRIX | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 5.83 | DRUG MATRIX | |||||
Kappa-type opioid receptor | GPCR | Ki | 5.58 | DRUG MATRIX | |||||
Delta-type opioid receptor | GPCR | Ki | 5.92 | DRUG MATRIX | |||||
Acetylcholinesterase | Enzyme | IC50 | 4.73 | DRUG MATRIX | |||||
Cytochrome P450 2C9 | Enzyme | IC50 | 6.70 | DRUG MATRIX | |||||
Aromatase | Enzyme | IC50 | 6.22 | CHEMBL | |||||
Epidermal growth factor receptor | Kinase | IC50 | 4.53 | DRUG MATRIX | |||||
Substance-P receptor | GPCR | Ki | 5.43 | DRUG MATRIX | |||||
Steroid 17-alpha-hydroxylase/17,20 lyase | Enzyme | Ki | 6.61 | CHEMBL | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 7.80 | DRUG MATRIX | |||||
Alkaline phosphatase, tissue-nonspecific isozyme | Enzyme | EC50 | 4.15 | CHEMBL | |||||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.38 | DRUG MATRIX | |||||
Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 4.56 | DRUG MATRIX | |||||
Thromboxane-A synthase | Enzyme | IC50 | 6.58 | DRUG MATRIX | |||||
Lanosterol 14-alpha demethylase | Enzyme | IC50 | 6.70 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 5.42 | CHEMBL | |||||
Type-2 angiotensin II receptor | GPCR | Ki | 5.11 | DRUG MATRIX | |||||
Substance-K receptor | GPCR | Ki | 5.79 | DRUG MATRIX | |||||
Melanocortin receptor 4 | GPCR | Ki | 4.92 | DRUG MATRIX | |||||
Melanocortin receptor 5 | GPCR | Ki | 4.67 | DRUG MATRIX | |||||
Melanocortin receptor 3 | GPCR | Ki | 4.79 | DRUG MATRIX | |||||
Malate dehydrogenase cytoplasmic | Enzyme | IC50 | 4.60 | CHEMBL | |||||
Calcium release-activated calcium channel protein 1 | Ion channel | IC50 | 4.57 | CHEMBL | |||||
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase | Enzyme | IC50 | 5.82 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 4.40 | CHEMBL | |||||
Androgen receptor | Transcription factor | Ki | 5.33 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 5.03 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 5.69 | DRUG MATRIX | |||||
Progesterone receptor | Transcription factor | Ki | 5.71 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 4.94 | CHEMBL | |||||
Acetylcholinesterase | Enzyme | IC50 | 4.67 | CHEMBL | |||||
Aromatase | Enzyme | EC50 | 6.40 | CHEMBL | |||||
Cholinesterase | Enzyme | IC50 | 5.17 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | Kd | 6.70 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 2 | Enzyme | IC50 | 5.17 | CHEMBL | |||||
Mycocyclosin synthase | Enzyme | Kd | 7.14 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.75 | CHEMBL | |||||
Fatty acid hydroperoxide lyase, chloroplastic | Enzyme | IC50 | 4.19 | CHEMBL | |||||
Sodium/potassium-transporting ATPase subunit alpha-2 | Ion channel | IC50 | 4.72 | DRUG MATRIX |
ID | Source |
---|---|
4018555 | VUID |
N0000146875 | NUI |
D00416 | KEGG_DRUG |
22832-87-7 | SECONDARY_CAS_RN |
4018554 | VANDF |
4018555 | VANDF |
C0025942 | UMLSCUI |
CHEBI:6923 | CHEBI |
CHEMBL91 | ChEMBL_ID |
CHEMBL1559 | ChEMBL_ID |
D008825 | MESH_DESCRIPTOR_UI |
DB01110 | DRUGBANK_ID |
4189 | PUBCHEM_CID |
2449 | IUPHAR_LIGAND_ID |
2728 | INN_ID |
7NNO0D7S5M | UNII |
42790 | RXNORM |
1135 | MMSL |
36502 | MMSL |
5112 | MMSL |
5113 | MMSL |
7143 | MMSL |
d00155 | MMSL |
002918 | NDDF |
002919 | NDDF |
372738006 | SNOMEDCT_US |
42720001 | SNOMEDCT_US |
60727003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Good Sense Miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0113-0214 | CREAM | 2 g | VAGINAL | ANDA | 17 sections |
good sense miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0113-0825 | CREAM | 2 g | VAGINAL | ANDA | 17 sections |
basic care miconazole 3 | HUMAN OTC DRUG LABEL | 1 | 0113-7070 | CREAM | 40 mg | VAGINAL | ANDA | 17 sections |
basic care miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0113-7825 | CREAM | 2 g | VAGINAL | ANDA | 17 sections |
Selan Antifungal | HUMAN OTC DRUG LABEL | 1 | 0159-2500 | CREAM | 2 g | TOPICAL | OTC monograph final | 12 sections |
Selan Antifungal | HUMAN OTC DRUG LABEL | 1 | 0159-2500 | CREAM | 2 g | TOPICAL | OTC monograph final | 12 sections |
Desenex | HUMAN OTC DRUG LABEL | 1 | 0316-0225 | POWDER | 20 mg | TOPICAL | OTC monograph final | 13 sections |
Zeasorb | HUMAN OTC DRUG LABEL | 1 | 0316-0231 | POWDER | 20 mg | TOPICAL | OTC monograph final | 12 sections |
Zeasorb | HUMAN OTC DRUG LABEL | 1 | 0316-0232 | POWDER | 20 mg | TOPICAL | OTC monograph final | 12 sections |
Athletes Foot | HUMAN OTC DRUG LABEL | 1 | 0363-0557 | SPRAY | 2 g | TOPICAL | OTC monograph final | 13 sections |
Miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0363-0730 | CREAM | 20 mg | VAGINAL | ANDA | 17 sections |
Jock Itch | HUMAN OTC DRUG LABEL | 1 | 0363-1497 | SPRAY | 2 g | TOPICAL | OTC monograph final | 13 sections |
miconazole 3 | HUMAN OTC DRUG LABEL | 1 | 0363-2070 | CREAM | 40 mg | VAGINAL | ANDA | 17 sections |
Miconazole Nitrate | HUMAN OTC DRUG LABEL | 1 | 0363-3115 | POWDER | 1.42 g | TOPICAL | OTC monograph final | 13 sections |
Miconazole Nitrate | HUMAN OTC DRUG LABEL | 1 | 0363-4208 | SPRAY | 3 g | TOPICAL | OTC monograph final | 13 sections |
Miconazole Nitrate 2% | HUMAN OTC DRUG LABEL | 1 | 0363-5353 | AEROSOL, SPRAY | 1.30 g | TOPICAL | OTC monograph final | 14 sections |
Miconazole Nitrate | HUMAN OTC DRUG LABEL | 1 | 0363-7418 | AEROSOL, SPRAY | 2.60 g | TOPICAL | OTC monograph final | 13 sections |
VUSION | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0378-8222 | OINTMENT | 2.50 mg | TOPICAL | NDA authorized generic | 26 sections |
VUSION | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0378-9730 | OINTMENT | 2.50 mg | TOPICAL | NDA | 26 sections |
Miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0472-0730 | CREAM | 20 mg | VAGINAL | ANDA | 17 sections |
Antifungal | HUMAN OTC DRUG LABEL | 1 | 0472-0735 | CREAM | 20 mg | TOPICAL | OTC monograph final | 13 sections |
Miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0472-1736 | SUPPOSITORY | 100 mg | VAGINAL | ANDA | 17 sections |
Miconazole Nitrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0472-1738 | SUPPOSITORY | 200 mg | VAGINAL | ANDA | 16 sections |
Miconazole Nitrate | HUMAN OTC DRUG LABEL | 1 | 0536-1134 | CREAM | 20 mg | TOPICAL | OTC MONOGRAPH FINAL | 14 sections |
Miconazole Nitrate | HUMAN OTC DRUG LABEL | 1 | 0713-0197 | SUPPOSITORY | 100 ug | VAGINAL | ANDA | 11 sections |
Miconazole Nitrate | HUMAN OTC DRUG LABEL | 1 | 0713-0252 | CREAM | 20 mg | VAGINAL | ANDA | 11 sections |
fungoid tincture | HUMAN OTC DRUG LABEL | 1 | 0884-0293 | TINCTURE | 20 mg | TOPICAL | OTC monograph final | 12 sections |
Miconazole 7 | HUMAN OTC DRUG LABEL | 1 | 0904-7734 | CREAM | 20 mg | VAGINAL | ANDA | 16 sections |
Miconazole Nitrate Antifungal Powder | HUMAN OTC DRUG LABEL | 1 | 10135-720 | POWDER | 2 g | TOPICAL | OTC monograph final | 10 sections |
TRIPLEAF | HUMAN OTC DRUG LABEL | 1 | 11086-040 | PASTE | 2 g | TOPICAL | OTC monograph final | 11 sections |